

## **SSG Working group meeting Dec 1-2, 2008 Copenhagen**

### **Report from the Oncology subcommittee, bone sarcomas**

#### **SSG XIV.**

The protocol was closed Dec 2005. In total 63 eligible patients with non-metastatic, extremity localized osteosarcoma were included in the analysis. Final report will be presented as a jubilee booklet article. Briefly, oncological outcomes are better than in previous SSG studies. However, salvage therapy with addition of high-dose ifosfamide failed to improve outcome for poor histological responders.

#### **EURAMOS**

By Oct 2008 1179 patients including 58 (5 %) SSG patients are recruited and 658 patients are randomized. Thus, EURAMOS-1 is the largest and fastest recruiting osteosarcoma trial ever. Inclusion rate is on target, but less than expected patients are randomized (65 % vs 90%) and more than expected patients are good responder (54 % vs 45 %). The trial management group has therefore decided to extend the recruitment period with one year to June 2010.

#### **EUROBOSS**

By Nov 2008 160 patients are registered from ISG, COSS and SSG (n=36) and the study is the largest prospective series of patients in this category (high-grade bone, > 40y). No new patient registered from SSG in 2008. The planned chemotherapy is feasible with one toxic death reported so far (male, 65 y, ISG). The study will continue until end 2009. An abstract is submitted to ASCO 2009. Three co-authors from SSG, M Eriksson, KS Hall and S Smeland.

#### **Ewing's family tumors**

ISGSSG III study is closed (Dec 2006) and patients with localized disease not included in studies (EE99) are treated according to ISGSSG III as standard therapy. Preliminary results were presented at ASCO 2007, and the strategy to boost poor responder with HD-BuM seems to improve their prognosis to a similar level as for good responders. The overall data for the SSG cohort is excellent compared to previous SSG studies in EFT. A manuscript is in preparation (Ferrari first author). Regarding next protocol no decision is taken. An option is to join in with Euro-Ewing with their next protocol (2009?).

#### **Radiotherapy in axial located Ewing sarcoma treated with HD-BuM**

Concern about the toxicity with the combination of radiotherapy and HD-BuM has been addressed from the French pediatric oncology group based on several cases with treatment related death (TRD). A survey has revealed that all cases with death or myelitis were associated with high doses of radiotherapy (more than prescribed in the protocol). In total, 12 TRD have been reported from the EE99 trial and 4 of those received RxT for axial locations. In SSG no TRD has been reported among 23 patients treated with HD-BuM. One case of severe colitis has been reported. The conclusion was that the increased toxicity seen in EE99/French patients was based on bad radiology rather than an increased risk of severe side effects by combination therapy. Therefore, no change in standard therapy was decided. To improve quality of radiotherapy delivery a group of experts (Engellau, Monge and Bruland) reviewing all treatment plans was appointed. The first task is to establish a logistic for exchange of treatment plans among the involved centers.

#### **Establishment of a subcommittee in SSG for long-term side effects/cancer survivorship.**

The group agreed that SSG as a group has a responsibility to take part in the organization of a long-term follow-up program for sarcoma patients. Chairman and members and will be appointed at the next board meeting.